Effect of Statin Recombinant Drug on Metabolic Syndrome

PHARMACOLOGY REPORT 1
To evaluate the effect of Statin Recombinant drug (RSD) drug on metabolic syndrome
Report
Students Name
University
Campus

Experimental Report 2
Abstract
Metabolic syndrome is a health condition which is initiated by insulin resistance and
couple up with other metabolic disorders. Metabolic syndrome is diagnosed with elevated levels;
of obesity, triglycerides, high blood pressure, and fasting glucose. There is an increased global
prevalence of metabolic syndrome and this has led to the introduction of new medication
approaches being developed to address the condition. Common medication approach is the use of
the statin. They have tolerable effects on treating and managing dyslipidemia. However, with the
shortcomings observed, new recombinant drug management has been formulated and thus this
randomized study aimed at evaluating its effects on managing metabolic syndrome. This
experimental study adopted randomized control double-blind study it passed three populations
groups which include; normal population, control group, and treatment group. The recombinant
drug was assessed with glucose, insulin, total cholesterol and triglyceride variables. The results
of the study showed improved clinical outcome and highly significant effect of the drug with the
key variables being assessed, with the levels of glucose (0.004), insulin (0.0001), total
cholesterol (0.001), and triglycerides (0.002) significant at 95% CI. Thus with the results of this
study, the new drug regime RSD has huge significant impacts on reducing lipid levels thus
reducing the effects of metabolic syndrome.

Experimental Report 3
Evaluation of the effect of Statin Recombinant drug (RSD) drug on metabolic syndrome
Report
Metabolic syndrome also referred to as insulin resistance is a group of metabolic
disorders which have its effects on glucose intolerance, resistance to insulin, dyslipidemia and
glucose intolerance. A criterion for diagnosing metabolic syndrome follows a central obesity
patient and raised triglycerides, decrease high blood pressure and elevated fasting glucose
plasma. Metabolic syndrome is a serious public health issue due to its related global
prevalence. The disorder has effects on the increased occurrence of hypertension, type II
diabetes and heart-related diseases, (Hosseini-Esfahani et al., 2014 pp 106-108).
Metabolic syndrome prevalence often varies across the populations based on ethnicity,
age, and gender. Studies undertaken in Tehran by Prevention and Metabolic Disorders
Research Center found out that among 4018 subjects aged above 40 years, the prevalence of
metabolic syndrome was found to be 51.4 %(Hadaegh, Shafiee, Ghasemi & Sarbakhsh, 2010).
This high prevalence rate endangers huge population of Iran at elevated risks linked to
cardiovascular. Among South Asians, metabolic syndrome predisposes patients with more and
elevated occurrence of type 2 diabetes mellitus and coronary heart disease. Cardiovascular risk
factors were initially supported with students undertaken in Europe, where reports of a high
prevalence of metabolic syndrome occur, (Hadaegh et al., 2012 pp 430).
The associated clinical repercussions of the metabolic syndrome involve making changes
on glucose and lipid homeostasis which play a role in the insensitivity. Insulin resistance can
have an influence on the dyslipidemia state which has an enhanced level of hepatic
glucogenesis, the output of glucose and low cholesterol secretion. The occurrence of
postprandial suppression of adipose tissue has an effect on the adipose tissue lipolysis leading
to increased levels of insulin sensitivity which has a subsequent effect on hyperinsulinemia,
(Derakhashan & Balaee, 2010 pp 210).